- Home
- BRIA vs IRD Comparison
BRIA vs IRD Comparison
Compare BRIA & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRIA
- IRD
- Stock Information
- Founded
- BRIA 2011
- IRD 2018
- Country
- BRIA Singapore
- IRD United States
- Employees
- BRIA N/A
- IRD N/A
- Industry
- BRIA
- IRD
- Sector
- BRIA
- IRD
- Exchange
- BRIA NYSE
- IRD NYSE
- Market Cap
- BRIA 58.5M
- IRD 62.0M
- IPO Year
- BRIA 2024
- IRD N/A
- Fundamental
- Price
- BRIA $2.30
- IRD $0.93
- Analyst Decision
- BRIA
- IRD Strong Buy
- Analyst Count
- BRIA 0
- IRD 3
- Target Price
- BRIA N/A
- IRD $6.33
- AVG Volume (30 Days)
- BRIA 5.3K
- IRD 2.9M
- Earning Date
- BRIA 08-15-2025
- IRD 08-15-2025
- Dividend Yield
- BRIA N/A
- IRD N/A
- EPS Growth
- BRIA N/A
- IRD N/A
- EPS
- BRIA 92.24
- IRD N/A
- Revenue
- BRIA $59,695,825.00
- IRD $13,651,000.00
- Revenue This Year
- BRIA N/A
- IRD $51.41
- Revenue Next Year
- BRIA N/A
- IRD $68.84
- P/E Ratio
- BRIA $0.02
- IRD N/A
- Revenue Growth
- BRIA 8.03
- IRD N/A
- 52 Week Low
- BRIA $1.78
- IRD $0.65
- 52 Week High
- BRIA $4.38
- IRD $2.18
- Technical
- Relative Strength Index (RSI)
- BRIA N/A
- IRD N/A
- Support Level
- BRIA N/A
- IRD N/A
- Resistance Level
- BRIA N/A
- IRD N/A
- Average True Range (ATR)
- BRIA 0.00
- IRD 0.00
- MACD
- BRIA 0.00
- IRD 0.00
- Stochastic Oscillator
- BRIA 0.00
- IRD 0.00
About BRIA BRILLIA INC
BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.